Modality
Gene Therapy
MOA
CGRPant
Target
EZH2
Pathway
JAK/STAT
MDDMCCPBC
Development Pipeline
Preclinical
~Apr 2011
→ ~Jul 2012
Phase 1
~Oct 2012
→ ~Jan 2014
Phase 2
~Apr 2014
→ ~Jul 2015
Phase 3
~Oct 2015
→ ~Jan 2017
NDA/BLA
Apr 2017
→ May 2030
NDA/BLACurrent
NCT06304558
1,467 pts·MCC
2017-04→2030-05·Completed
1,467 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-044.1y awayPh3 Readout· MCC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2030-05-04 · 4.1y away
MCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06304558 | NDA/BLA | MCC | Completed | 1467 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |